Your browser doesn't support javascript.
Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM)
Diabetol Metab Syndr ; Jul(9): 53-53, 2017.
Artigo em Inglês | Sec. Est. Saúde SP, SESSP-IDPCPROD, Sec. Est. Saúde SP | ID: ses-36559
Biblioteca responsável: BR79.1
Localização: BR79.1
ABSTRACT
BACKGROUND: Since the first position statement on diabetes and cardiovascular prevention published in 2014 by the Brazilian Diabetes Society, the current view on primary and secondary prevention in diabetes has evolved as a result of new approaches on cardiovascular risk stratification, new cholesterol lowering drugs, and new anti-hyperglycemic drugs. Importantly, a pattern of risk heterogeneity has emerged, showing that not all diabetic patients are at high or very high risk. In fact, most younger patients who have no overt cardiovascular risk factors may be more adequately classified as being at intermediate or even low cardiovascular risk. Thus, there is a need for cardiovascular risk stratification in patients with diabetes. The present panel reviews the best current evidence and proposes a practical risk-based approach on treatment for patients with diabetes. MAIN BODY: The Brazilian Diabetes Society, the Brazilian Society of Cardiology, and the Brazilian Endocrinology and Metabolism Society gathered to form an expert panel including 28 cardiologists and endocrinologists to review the best available evidence and to draft up-to-date an evidence-based guideline with practical recommendations for risk stratification and prevention of cardiovascular disease in diabetes. The guideline includes 59 recommendations covering: (1) the impact of new anti-hyperglycemic drugs and new lipid lowering drugs on cardiovascular risk; (2) a guide to statin use, including new definitions of LDL-cholesterol and in non-HDL-cholesterol targets; (3) evaluation of silent myocardial ischemia and subclinical atherosclerosis in patients with diabetes; (4) hypertension treatment; and (5) the use of antiplatelet therapy...(AU)
Assuntos

Similares

MEDLINE

...
LILACS

LIS

Coleções: Bases de dados nacionais / Brasil Base de dados: Sec. Est. Saúde SP / SESSP-IDPCPROD Assunto principal: Sangue / Doença da Artéria Coronariana / Fatores de Risco / Diabetes Mellitus / Dislipidemias / Glucose / Hipertensão Tipo de estudo: Guia de prática clínica Aspecto clínico: Etiologia País/Região como assunto: América do Sul / Brasil Idioma: Inglês Revista: Diabetol Metab Syndr Ano de publicação: 2017 Tipo de documento: Artigo Instituição/País de afiliação: Centro de Diabetes de Belo Horizonte/Brasil / Clínica de Endocrinologia e Metabologia/Brasil / Faculdade de Ciências Médicas de Minas Gerais/Brasil / Faculdade de Ciências, Médicas da Santa Casa de São Paulo/Brasil / Faculdade de Medicina de São José do Rio Preto/Brasil / Faculdade de Medicina, Universidade Federal do Rio Grande do Sul/Brasil / Instituto Dante Pazzanese de Cardiologia/Brasil / Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione/Brasil / Pontifícia Universidade Católica de Campinas (PUC-Campinas)/Brasil / UFRGS/Brasil